IVRO Stock — Invitro International

Invitro International (IVRO)

Updated October 16, 2026.

IVRO is a Stock. Total return is 50.0% over the past 25.3 years, 837.3 points behind SPY at 887.3%.

InVitro International develops and commercializes non-animal testing products and services, primarily for assessing the irritancy and corrosivity of chemicals and consumer products used in cosmetics, pharmaceuticals, and industrial applications. The company does not currently have an established distribution to shareholders. The business appeals to investors interested in healthcare innovation and alternative testing methodologies, though those seeking regular dividend income would look elsewhere.

IVRO performance versus SPY

Price and return data through 2026-10-16.

Total return is 50.0% over the past 25.3 years, 837.3 points behind SPY at 887.3%. Over the past year its total return — price change plus distributions reinvested — is -22.1%. Its deepest 1-year drawdown was 67.3%.

IVRO key facts

Asset type

Stock

Asset class

Equity

Inception date

06/21/2001

Distribution frequency

None

Last close

$0.06 (as of 2026-10-16)

Market cap

$1,335,589

Average volume

1000.0

Beta

-0.806

Payout ratio

0.0%

EPS

$0.00

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IVRO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 67.3%.

Who may consider IVRO — and who may not

It is a weaker fit for investors who need monthly cash flow (IVRO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on IVRO

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions